Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is accompanied by side effects affecting health-related quality of life (HRQL).
Objective: To assess the effects of the fetal estrogen estetrol (E4) on symptoms related to estrogen and androgen deficiency, and on HRQL measured using the validated Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire.
Design Setting And Participants: This was a phase 2, double-blind, randomized, placebo-controlled study in patients with advanced PCa.
Intervention: Patients receiving ADT were randomly assigned at a 2:1 ratio to daily treatment with a high dose of E4 (HDE4; = 41) or placebo ( = 21) for 24 wk.
Outcome Measurements And Statistical Analysis: The primary outcome was the effect of HDE4 cotreatment on hot flushes (HFs). Secondary outcomes were the Q-Man questionnaire for evaluation of the effect on estrogen and androgen deficiency symptoms, and the FACT-P questionnaire for evaluating HRQL.
Results And Limitations: At 24 wk, the number of patients experiencing HFs was significantly lower in the HDE4 group than in the placebo group (14.3% vs 60.0%; < 0.001). HDE4 treatment was associated with lower incidence of night sweats, arthralgia, and fatigue, but more nipple tenderness and gynecomastia. At 24 wk, the mean HRQL score favored HDE4 over placebo for the FACT-P total score (122.2 ± 12.3 vs 118.7 ± 19.7) and for several other FACT subscales.
Conclusions: Daily HDE4 coadministration almost completely prevented HFs in patients with advanced PCa treated with ADT. HDE4 also had positive effects on HRQL and counteracted other estrogen deficiency symptoms caused by ADT. These data support the dual efficacy concept of ADT and HDE4 to improve HRQL and increase the antitumor effect of ADT.
Patient Summary: For patients on androgen deprivation therapy for advanced prostate cancer, cotreatment with a high dose of estetrol almost completely prevents the occurrence of hot flushes and improves quality of life and well-being, but nipple sensitivity and an increase in breast size may occur.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637725 | PMC |
| http://dx.doi.org/10.1016/j.euros.2022.09.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phytoestrogens: Pharmacological Potential and Therapeutic Insights for Urinary Tract Infections.
Phytother Res
December 2024
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Urinary tract infections (UTIs) are exceptionally common in postmenopausal female or patients with diabetes mellitus or nephrolithiasis, carrying substantial burden on patients and healthcare system. Increasing proportion and ongoing spread of antibiotic-resistant pathogens have further debilitated the condition in battlefield against the UTIs. Lack of estrogen may contribute to high inclination of UTIs after menopause and hormone replacement therapy can mitigate symptoms of hot flashes, vaginal dryness and UTIs, rationalizing the usage of estrogen and analogues in treatment and prophylaxis of UTIs.
View Article and Find Full Text PDFSafety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies.
Adv Ther
December 2024
Astellas Pharma Global Development, Northbrook, IL, USA.
Introduction: This study evaluated the safety and tolerability of fezolinetant in women with vasomotor symptoms (VMS) due to menopause in a pooled analysis of data from three 52-week phase 3 studies (SKYLIGHT 1, 2, and 4).
Methods: SKYLIGHT 1 and 2 were double-blind, placebo-controlled studies where women (≥ 40 to ≤ 65 years), with moderate to severe VMS (minimum average ≥ 7 hot flashes/day) were randomized to once-daily placebo, fezolinetant 30 mg or 45 mg. After 12 weeks, those on placebo were re-randomized to fezolinetant 30 mg or 45 mg, while those on fezolinetant continued on their assigned dose for 40 weeks.
A study on anxiety and depression symptoms among menopausal women: a web based cross sectional survey.
Front Public Health
December 2024
Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Background: An essential part of aging is menopause, which indicates the final phase of the female reproductive cycle. The objective of this research was to assess anxiety and depressive symptoms among menopausal women in Asir region, Saudi Arabia.
Methods: The cross-sectional survey was carried out in February to June 2024, using a random sampling procedure, study participants were selected.
Effectiveness, pharmacokinetics, and safety of triptorelin acetate microspheres in patients with locally advanced and metastatic prostate cancer.
Ther Adv Med Oncol
December 2024
Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang 310003, China.
Background: A newly generic microspheres, sustained-release formulation of triptorelin acetate 3.75 mg has been developed.
Objectives: To evaluate the efficacy, pharmacokinetics, and safety of triptorelin 1-month formulation in Chinese patients with prostate cancer.
A cultural adaptation and testing on the reliability and validity of the Chinese version of the Menopause Symptom Assessment Scale.
Menopause
January 2025
From the Department of Quality Control, Yuebei People's Hospital, Shantou University Medical College, Shaoguan, China.
Objective: The aim of this study was to modify the Chinese version of the Menopause Symptom Assessment Scale (MSAS) and evaluate its validity and reliability.
Methods: An expert panel from the gynecology and nursing domain determined items that should remain or be revised, and 30 participants were selected for the pilot study. A total of 255 women who met the criteria for inclusion were enrolled in the investigation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!